-
2
-
-
0032538246
-
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
-
Center for Disease Control and Prevention CDC
-
Center for Disease Control and Prevention (CDC). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recommen Rep. 1998;47(RR-19):1-39.
-
(1998)
MMWR Recommen Rep
, vol.47
, Issue.RR-19
, pp. 1-39
-
-
-
3
-
-
0033584440
-
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
-
Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-62.
-
(1999)
N Engl J Med
, vol.341
, Issue.8
, pp. 556-562
-
-
Alter, M.J.1
Kruszon-Moran, D.2
Nainan, O.V.3
-
4
-
-
0036829649
-
-
National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36(5 Suppl 1):S3-S20.
-
National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36(5 Suppl 1):S3-S20.
-
-
-
-
5
-
-
1642320241
-
Understanding hepatitis C
-
McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(2 Suppl):S21-S29.
-
(2004)
Am J Manag Care
, vol.10
, Issue.2 SUPPL.
-
-
McHutchison, J.G.1
-
6
-
-
27644542713
-
Chronic hepatitis C: An age Wave of disease burden
-
McHutchison JG, Bacon BR. Chronic hepatitis C: an age Wave of disease burden. Am J Manag Care. 2005;11(10 Suppl):S286-S295.
-
(2005)
Am J Manag Care
, vol.11
, Issue.10 SUPPL.
-
-
McHutchison, J.G.1
Bacon, B.R.2
-
7
-
-
0030031879
-
Hepatitis C virus genotypes in different risk populations in Spain. The Hepatitis-HIV Spanish Study Group
-
Bravo R, Soriano V, Garcia-Samaniego J, et al. Hepatitis C virus genotypes in different risk populations in Spain. The Hepatitis-HIV Spanish Study Group. J Infect Dis. 1996;173(2):509-10.
-
(1996)
J Infect Dis
, vol.173
, Issue.2
, pp. 509-510
-
-
Bravo, R.1
Soriano, V.2
Garcia-Samaniego, J.3
-
8
-
-
0032547938
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
-
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-92.
-
(1998)
N Engl J Med
, vol.339
, pp. 1485-1492
-
-
McHutchison, J.G.1
Gordon, S.C.2
Schiff, E.R.3
-
9
-
-
0032585237
-
Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
-
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352(9138):1426-32.
-
(1998)
Lancet
, vol.352
, Issue.9138
, pp. 1426-1432
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
-
10
-
-
0034324083
-
Pegylated interferon alfa-2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
-
Glue P, Fang JW, Rourizer-Panis R, et al. Pegylated interferon alfa-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68(5):556-67.
-
(2000)
Clin Pharmacol Ther
, vol.68
, Issue.5
, pp. 556-567
-
-
Glue, P.1
Fang, J.W.2
Rourizer-Panis, R.3
-
11
-
-
32344431567
-
Chronic hepatitis C virus management: 2000-2005 update
-
Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother. 2006;40(1):74-82.
-
(2006)
Ann Pharmacother
, vol.40
, Issue.1
, pp. 74-82
-
-
Hughes, C.A.1
Shafran, S.D.2
-
12
-
-
0035934568
-
Pegylated interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, et al. Pegylated interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
13
-
-
30044432484
-
American Gastroenterological Association technical review on the management of hepatitis C
-
Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130(1):231-64.
-
(2006)
Gastroenterology
, vol.130
, Issue.1
, pp. 231-264
-
-
Dienstag, J.L.1
McHutchison, J.G.2
-
14
-
-
27644514603
-
Treatment issues with chronic hepatitis C: Special populations and pharmacy strategies
-
Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care. 2005;11(10 Suppl):S296-S306.
-
(2005)
Am J Manag Care
, vol.11
, Issue.10 SUPPL.
-
-
Bacon, B.R.1
McHutchison, J.G.2
-
15
-
-
0036788338
-
Adherence tp combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
-
McHutchison JG, Manns M, Patel K, et al. Adherence tp combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-69.
-
(2002)
Gastroenterology
, vol.123
, Issue.4
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
-
16
-
-
33646434799
-
Clinical pharmacists and inpatient medical care: A systematic review
-
Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955-64.
-
(2006)
Arch Intern Med
, vol.166
, Issue.9
, pp. 955-964
-
-
Kaboli, P.J.1
Hoth, A.B.2
McClimon, B.J.3
Schnipper, J.L.4
-
17
-
-
39649123695
-
The impact of clinical pharmacists on drug-related problems and clinical outcomes
-
Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicoil. 2008;102(3):275-80.
-
(2008)
Basic Clin Pharmacol Toxicoil
, vol.102
, Issue.3
, pp. 275-280
-
-
Viktil, K.K.1
Blix, H.S.2
-
18
-
-
34447567398
-
Chronic hepatitis C virus infection: A review for pharmacists
-
Rodis J. Chronic hepatitis C virus infection: a review for pharmacists. J Am Pharm Assoc. 2007;47(4):508-20.
-
(2007)
J Am Pharm Assoc
, vol.47
, Issue.4
, pp. 508-520
-
-
Rodis, J.1
-
19
-
-
51849106467
-
Treatment options for patients with hepatitis C: Role of pharmacists in optimizing treatment response and managing adverse events
-
Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy. 2008;28(9):1151-61.
-
(2008)
Pharmacotherapy
, vol.28
, Issue.9
, pp. 1151-1161
-
-
Smith, J.P.1
-
20
-
-
1842632416
-
Population-based hepatitis C surveillance and treatment in a national managed care organization
-
Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004;10(4):250-56.
-
(2004)
Am J Manag Care
, vol.10
, Issue.4
, pp. 250-256
-
-
Shatin, D.1
Schech, S.D.2
Patel, K.3
McHutchison, J.G.4
-
21
-
-
33947587903
-
Evaluation of a pharmacist-managed hepatitis C care clinic
-
Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health-Syst Pharm. 2007; 64(6):632-36.
-
(2007)
Am J Health-Syst Pharm
, vol.64
, Issue.6
, pp. 632-636
-
-
Smith, J.P.1
Dong, M.H.2
Kaunitz, J.D.3
-
22
-
-
24144456553
-
Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic
-
Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy. 2005;25(9):1230-41.
-
(2005)
Pharmacotherapy
, vol.25
, Issue.9
, pp. 1230-1241
-
-
Kolor, B.1
-
23
-
-
37849042201
-
Into the light: Strategies for battling hepatitis C
-
Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. Am J Manag Care. 2007;13(Suppl 12):S319-S326.
-
(2007)
Am J Manag Care
, vol.13
, Issue.SUPPL. 12
-
-
Bacon, B.R.1
McHutchison, J.G.2
-
24
-
-
37849049890
-
Making it happen: Managed care considerations in vanquishing hepatitis C
-
McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care. 2007;13(Suppl 12):S327-S336.
-
(2007)
Am J Manag Care
, vol.13
, Issue.SUPPL. 12
-
-
McHutchison, J.G.1
Bacon, B.R.2
Owens, G.S.3
-
25
-
-
58749112970
-
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin
-
Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;28(3):289-93.
-
(2008)
Aliment Pharmacol Ther
, vol.28
, Issue.3
, pp. 289-293
-
-
Weiss, J.J.1
Bhatti, L.2
Dieterich, D.T.3
-
26
-
-
34547222990
-
Virahep-C Study Group. Assessing the validity of self-reported medication adherence in hepatitis C treatment
-
Smith SC, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW; Virahep-C Study Group. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother. 2007;41(7):1116-23.
-
(2007)
Ann Pharmacother
, vol.41
, Issue.7
, pp. 1116-1123
-
-
Smith, S.C.1
Wahed, A.S.2
Kelley, S.S.3
Conjeevaram, H.S.4
Robuck, P.R.5
Fried, M.W.6
|